Contacts

Janka Brezániová

Partner

Read More

Emma Danks

Partner

Read More

Simon Jupp

Senior associate

Read More

Nick Karangizi

Senior associate

Read More

Nick Karangizi

Senior associate

Read More

Colin McCall

Partner

Read More

Madison Lawler

Associate

Read More

Olav Nemling

Partner

Read More

Jason Rawkins

Partner

Read More

Graham Samuel-Gibbon

Partner

Read More

Marcin Sroga

Counsel

Read More

Krystian Stanasiuk, LL.M.

Partner

Read More

Agnieszka Sztoldman

Senior associate

Read More
Contacts

Janka Brezániová

Partner

Read More

Emma Danks

Partner

Read More

Simon Jupp

Senior associate

Read More

Nick Karangizi

Senior associate

Read More

Nick Karangizi

Senior associate

Read More

Colin McCall

Partner

Read More

Madison Lawler

Associate

Read More

Olav Nemling

Partner

Read More

Jason Rawkins

Partner

Read More

Graham Samuel-Gibbon

Partner

Read More

Marcin Sroga

Counsel

Read More

Krystian Stanasiuk, LL.M.

Partner

Read More

Agnieszka Sztoldman

Senior associate

Read More

7 April 2020

Advising Glenmark on product portfolio sale

Taylor Wessing has advised Glenmark, the Mumbai-headquartered pharmaceutical company, on the sale of its central nervous system (CNS) product portfolio business in Poland.

The portfolio has been sold to Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of CNS disorders.

The Glenmark CNS commercial team in Poland has also joined Neuraxpharm Polska’s existing sales and marketing organisation to create a strong player in the Polish CNS market. 

Glenmark’s established portfolio of 20 proprietary CNS products comprise both prescription medicines and Consumer Healthcare products. Lead products include the branded generics Cital® and Lamotrix®, both relevant brands in their respective markets.

This complex transaction drew on the deep expertise offered by the firm’s market-leading life sciences M&A practice including lawyers from both the corporate and intellectual property teams.

Commenting on the deal, Emma Danks, Co-head of International Corporate at Taylor Wessing said:

Glenmark is a leader in CNS products, and it makes good commercial sense that Neuraxpharm sees the opportunity to incorporate Glenmark's portfolio into its own business. This was a very exciting deal to have worked on as it hits our sweet spot, leveraging our specialist knowledge of the life sciences and pharmaceutical sectors together with our cross-border M&A expertise, with an international Taylor Wessing team from the United Kingdom, Poland and the Czech Republic”

The team was led by corporate partner Emma Danks and intellectual property partner Colin McCall with the support of corporate associate Nick Karangizi and intellectual property associate Lucy Sharples in the United Kingdom.

In addition, partner Graham Samuel-Gibbon and associate Madison Lawler advised on tax, and partner Jason Rawkins and associate Simon Jupp advised on intellectual property matters.

Further advice was given by corporate partner Olav Nemling, employment partner Krystian Stanasiuk, tax counsel Marcin Sroga, intellectual property senior associate Dr.Agnieszka Sztoldman in Poland and corporate partner Janka Brezaniova in the Czech Republic.


Taylor Wessing poskytla právní poradenství skupině Glenmark

Mezinárodní advokátní kancelář Taylor Wessing poskytla právní poradenství farmaceutické skupině Glenmark, s centrálou v indické Mumbaji, a to v souvislosti s prodejem jejího produktového portfolia centrálního nervového systému (CNS) v Polsku. Portfolio bylo prodáno Neuraxpharm, přední evropské farmaceutické skupině zaměřené na léčbu poruch CNS. Poskytnuté poradenství obsahovalo i aspekty skorporátním přesahem do České republiky.

 

Za českou část se na transakci podílela Janka Brezániová, partnerka Taylor Wessing Česká republika, se svým týmem. Brezániová komentuje:

Jsem ráda, že i v této složitější době se nám daří dotahovat transakce do úspěšného konce, za což určitě mimo jiné vděčíme i efektivní týmové spolupráci v rámci mezinárodní sítě Taylor Wessing.“

Tato komplexní přeshraniční transakce poskytla Taylor Wessing příležitost využít své rozsáhlé expertizy a zkušeností v sektoru Life Sciences, ať již co se týká oblasti fúzí a akvizic, korporátního práva nebo práva duševního vlastnictví. Na transakci se podíleli týmy Taylor Wessing ze Spojeného království Velké Británie a Severního Irska, Polska a České republiky.  

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

office-building-facades
Private equity

Advising The Rohatyn Group on investment in Optimapharm d.d.

22 May 2020

by multiple authors

Click here to find out more

Taylor Wessing announces three new senior promotions

4 November 2019

by multiple authors

Click here to find out more